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Lactococcus lactis is a nonpathogenic and noncolonizing bacterium which is being developed as a vaccine
delivery vehicle for immunization by mucosal routes. To determine whether lactococci can also deliver cyto-
kines to the immune system, we have constructed novel constitutive expression strains of L. lactis which
accumulate a test antigen, tetanus toxin fragment C (TTFC), within the cytoplasmic compartment and also
secrete either murine interleukin-2 (IL-2) or IL-6. When mice were immunized intranasally with various
different expression strains of L. lactis, the anti-TTFC antibody titers increased more rapidly and were
substantially higher in mice immunized with the bacterial strains which secreted IL-2 or IL-6 in addition to
their production of TTFC. This adjuvant effect was lost when the recombinant strains of L. lactis were killed
by pretreatment with mitomycin C and could therefore be attributed to the secretion of IL-2 or IL-6 by the
recombinant lactococci. These results provide the first example of the use of a cytokine-secreting, noninvasive
experimental bacterial vaccine vector to enhance immune responses to a coexpressed heterologous antigen and
point the way to experiments which will test the possible therapeutic efficacy of this mode of cytokine delivery.
The number of communicable diseases which might feasibly
be controlled by vaccination or treated by immunotherapy is
increasing rapidly, alongside advances in our understanding of
cellular and molecular biology as applied to the study of infec-
tious agents. However, virtually all of the numerous recombi-
nant antigen delivery systems developed to date have been
derived from attenuated pathogenic infectious agents, e.g., ra-
tionally attenuated Salmonella spp. (23, 38) or traditionally
attenuated Mycobacterium bovis (14).
By contrast, the use of Lactococcus lactis as a vaccine vector
is emerging as one of the most advanced prototypes of a pos-
sible new class of bacterial vaccines derived from noninvasive,
nonpathogenic gram-positive bacteria (45). L. lactis is a gram-
positive bacterium which is classified as “generally regarded as
safe” following its long history of use for the production of
fermented milk products. As a gram-positive nonpathogen, its
closest functional relative is Streptococcus gordonii, with which
it shares the capacity to serve as an antigen delivery vehicle for
mucosal immunization (22). Yet unlike S. gordonii, which is an
oral commensal bacterium, L. lactis lacks any known capacity
to multiply in vivo, except in gnotobiotic mice (15). Studies on
the feeding of live lactococci to animals and to human volun-
teers have shown that the passage of these bacteria through the
enteric tract is transitory, without any evidence of colonization
(15, 18).
The development of constitutive and inducible gene expres-
sion systems for L. lactis has recently made it possible to
undertake systematic investigations of the immunological ac-
tivity of experimental recombinant lactococcal vaccines (46).
We have been able to show that despite its lack of invasiveness,
L. lactis is able to deliver heterologous antigens to the systemic
and mucosal immune systems via mucosal routes (46). A num-
ber of antigens of protozoal, bacterial, and viral origin have
been efficiently expressed by us in L. lactis, but most of our
work to date has focused on studies of immune responses to
tetanus toxin fragment C (TTFC) and to the partially protec-
tive 28-kDa (glutathione S-transferase [SmGST]) immunogen
from Schistosoma mansoni (5) used as test immunogens.
Intranasal and oral immunization of mice with recombinant
L. lactis expressing TTFC or SmGST elicits significant serum
antibody responses against these antigens. In the case of
TTFC, these responses proved to be protective against lethal
challenge with 5 to 20 50% lethal doses of tetanus toxin (25,
32). Additionally, oral inoculation of lactococci expressing
TTFC significantly but transiently elevated the levels of anti-
TTFC immunoglobulin A (IgA) antibodies detected in the gut
secretions (32).
In the light of our previous results, the present study was
carried out to determine whether lactococci can deliver bio-
logically active molecules such as cytokines as well as heterol-
ogous antigens to the immune system. Cytokines produced by
subpopulations of T cells critically influence the balance be-
tween humoral and cell-mediated types of immune responses
and are potentially useful as immune response modulators for
vaccines and immunotherapeutic agents (40). Recombinant
strains of M. bovis BCG secreting functional mammalian cyto-
kines have been shown to be more potent stimulators of cell-
mediated immune responses than their nonrecombinant coun-
terparts in mouse models of experimental infection (24). By
contrast, antibody responses to whole bacterial cells, outer
membrane proteins, or lipopolysaccharide antigens of attenu-
ated Salmonella typhimurium were not augmented when these
strains were engineered to express interleukin-6 (IL-6), IL-1,
or IL-4 intracellularly (3, 7, 11). The influence of these cyto-
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kines on responses to heterologous antigens expressed by these
bacteria has not subsequently been investigated. In viral vector
systems, the coexpression of IL-6 has been shown to augment
both systemic and mucosal antibody responses to the viral
antigens (21, 30). In this study, murine IL-2 and IL-6 were
chosen for expression in L. lactis, as they have been shown to
enhance antibody titers to either vaccine antigens or inacti-
vated viral vaccines when parenterally administered either ex-
ogenously or in liposomal formulations (10, 16, 20, 35). Studies
both in vitro and in vivo have suggested a potential application
for IL-6 in augmenting IgA antibody responses in mucosal B
cells or at mucosal surfaces (26, 27, 30, 33). Additionally, it has
been shown that serum levels of IL-6 correlate with the serum
concentration of IgA in patients with alcoholic liver cirrhosis
and children infected with human immunodeficiency virus (8,
31), implicating its role in augmenting IgA synthesis in the
serum. Inclusion of IL-2 in liposomes containing bacterial
polysaccharide has also been shown to enhance antibody titers
of polysaccharide-specific secretory IgA and to increase the
numbers of polysaccharide-specific pulmonary plasma cells
more than 80-fold following intranasal immunization of mice
(1).
In this report, we present results which indicate that it is
possible to prepare genetic constructs in L. lactis which confer
on this organism the capacity to deliver physiologically active
quantities of murine IL-2 and IL-6 in vivo.
MATERIALS AND METHODS
Recombinant DNA techniques. PCR amplification of DNA was performed
with Vent polymerase and using conditions recommended by the manufacturer.
DNA-modifying enzymes and restriction endonucleases were used under stan-
dard conditions and in the buffers recommended by the manufacturers. General
molecular cloning techniques and the electrophoresis of DNA and proteins were
carried out essentially as described previously (34). L. lactis was transformed by
electroporation of cells grown in the presence of glycine (47), and Escherichia
coli was transformed by the electroporation method of Dower et al. (9).
Fractionation of lactococci and immunoblotting. Total-cell protein extracts of
L. lactis cells were prepared by the method of Wells et al. (48). To recover
proteins from the cell wall of lactococci, the cell wall was enzymatically digested
with mutanolysin and lysozyme in the presence of an osmotically stabilizing
buffer. Bacteria (approximately 2.5 3 109 CFU) were pelleted by centrifugation,
washed three times in Tris-buffered saline (0.15 M NaCl, 0.02 M Tris-HCl [pH
7.5]), resuspended in 200 ml of 20 mM Tris-HCl (pH 7.5)–10% (wt/vol) sucrose
containing mutanolysin (100 U/ml) and lysozyme (5 mg/ml), and incubated for
1 h at 37°C. After treatment with mutanolysin and lysozyme, the cells were
separated from enzymatically released cell wall material by centrifugation. En-
zymatically digested cell wall fractions and cell pellets were boiled for 3 min in
Laemmli sample buffer. Proteins were separated by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis and electroblotted onto nitrocellulose. The
transfer of protein was checked by reversibly staining the filter with Ponceau S,
after which TTFC and or murine cytokines were detected by immunoblotting as
previously described (36, 48).
Preparation of bacterial cells for immunization. L. lactis strains carrying
pTREX1, pT1TT, pT1TT-IL2, and pT1TT-IL6 were cultured at 30°C in M17
broth (Difco Ltd.) supplemented with 0.5% (wt/vol) glucose and 5 mg of eryth-
romycin per ml to mid-logarithmic growth phase. The cells were washed with
sterile phosphate-buffered saline (PBS) before resuspension in a solution of 0.2
M sodium bicarbonate (Sigma, Poole, Dorset, United Kingdom), 5% casein
hydrolysate [GIBCO Ltd., Paisley, United Kingdom), and 0.5% (wt/vol) glucose
(Sigma) at 5 3 1010 CFU/ml.
Mitomycin C pretreatment of bacteria. Cells from a fresh overnight culture at
2 3 108 CFU/ml were treated with 50 mg of mitomycin C (Sigma) per ml for 2 h
at 30°C. Aliquots of 1 ml were taken after incubation, and the concentration of
cells was determined by nephelometry. The cells were washed three times in
sterile PBS before spreading over GM17 agar plates containing the relevant
selective antibiotics in order to calculate the efficiency of killing. In each case,
fewer than 1 in 104 cells remained viable after treatment with mitomycin C. All
cells used for immunization were washed three times in a large excess of PBS
before resuspension at 5 3 1010 CFU/ml as described above.
Immunization protocol. Groups of six specific-pathogen-free female C57BL/6
mice (Harlan UK Ltd. Bicester, Oxon, United Kingdom), aged 6 to 8 weeks at
day 0, were immunized intranasally with recombinant L. lactis. Intranasal doses
of 109 cells in 20 ml were applied to lightly anesthetized animals, using a mi-
cropipette. Serum samples were taken at intervals of 14 days and were stored at
220°C until required.
ELISA for detection of TTFC-specific serum antibody. Using a method based
on that of Wells et al. (48), enzyme-linked immunosorbent assay (ELISA) plates
were coated overnight at 4°C with recombinant purified TTFC (50 ng/well;
Boehringer Mannheim, East Sussex, United Kingdom) in carbonate-bicarbonate
buffer (pH 9.6). Wells were blocked for 1 h at room temperature, using 3%
bovine serum albumin (BSA) (Sigma). Primary antisera were tested in duplicate
wells, using a twofold dilution series, including replicate wells of a 1/50-diluted
preimmune serum on every plate. After 90 min, secondary anti-mouse immuno-
globulin-alkaline phosphatase conjugates (Southern Biotechnology Associates,
Inc., Birmingham, Ala.) were applied before development, using n-nitrophenyl
phosphate (Sigma) as the substrate. Dilution curves were drawn for each sample,
and the endpoint titer was calculated as the dilution producing the same optical
density as the 1/50 dilution of a pooled preimmune serum. Statistical compari-
sons between groups were made by the Mann-Whitney U test. A P value of
.0.05 was considered nonsignificant.
ELISA for detection of antilactococcal serum antibody. An extract of soluble
lactococcal protein was prepared from the L. lactis control strain carrying
pTREX1 as previously described (48). The protein concentration of the cell
extract was determined by using a Bradford assay (Bio-Rad Laboratories, Hert-
fordshire, United Kingdom). ELISA plates were coated overnight with protein
extract in carbonate-bicarbonate buffer (pH 9.6) (50 ng/well) and then blocked
for 1 h at room temperature with 3% BSA (Sigma). Dilutions of the primary
antisera were tested in duplicate for antilactococcal antibody as described above
for the TTFC ELISA.
Assay of IgA in fecal material. Fresh fecal pellets were collected from each
group of mice and frozen at 220°C until the end of the experiment. Soluble fecal
extracts were prepared in 2-ml microcentrifuge tubes by adding 1 ml of PBS
containing 1% BSA and 1 mM freshly added phenylmethylsulfonyl fluoride per
0.1 mg of fecal material. The tubes were incubated overnight at 4°C to soften the
pellets and then vigorously mixed by vortexing to disrupt and suspend all solid
matter. The samples were then centrifuged at full speed in a microcentrifuge for
5 min to pellet the insoluble material. The supernatants were removed and
assayed for total IgA concentration, using a commercially available radial im-
munodiffusion test kit (The Binding Site, Birmingham, United Kingdom) ac-
cording to the manufacturer’s instructions.
RESULTS
Coexpression of TTFC and murine IL-2 or IL-6 in L. lactis.
To coexpress the test antigen (TTFC) together with a cytokine,
artificial operons were constructed within the lactococcal ex-
pression plasmid pTREX1 (Fig. 1) (46). This was achieved by
modifying a strain which expresses and accumulates the model
immunogen TTFC intracellularly so that it could additionally
coexpress and secrete murine IL-2 or IL-6.
Briefly, the DNA fragment encoding TTFC was amplified by
PCR and cloned between blunted SphI and BamHI sites in
pTREX1 to generate plasmid pT1TT, which expressed TTFC
intracellularly in L. lactis. To obtain secretion of the mamma-
lian cytokines by L. lactis, the eukaryotic secretion signal se-
quences present in the cDNAs of IL-2 and IL-6 were replaced
with the prokaryotic signal sequence of the lactococcal usp45
gene. Previous studies had shown that such fusions resulted in
the secretion of fully active cytokines into L. lactis culture
supernatants (36, 37). Initially the DNA fragments encoding
the mature processed form of murine IL-2 or IL-6 were cloned
into the lactococcal expression plasmid pLET2N (25). DNA
fragments encoding the lactococcal usp45 secretion signal-cy-
tokine fusion product and its upstream Shine-Dalgarno se-
quence were then cloned downstream of the TTFC gene in
pT1TT to generate pT1TT-IL2 and pT1TT-IL6 (Fig. 1). For
use as controls, we constructed two strains of L. lactis which
expressed only IL-2 or IL-6. These were constructed by cloning
PCR-amplified fragments encoding the L. lactis usp45 secre-
tion signal-cytokine fusion products and their upstream trans-
lation initiation region (initially constructed in pLET-based
plasmids) between the BamHI and BglII sites in pTREX1 (Fig.
1). The characteristics of the various different strains of recom-
binant L. lactis constructed are shown in Table 1.
Immunoblotting of equal amounts of cell extract prepared
from L. lactis strains carrying plasmid pT1TT, pT1TT-IL2, or
pT1TT-IL6 revealed that all three strains produced similar
amounts of TTFC (Fig. 2A). Cytokine bioassays carried out on
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culture supernatants harvested from exponentially growing
cultures showed that biologically active IL-2 and IL-6 were
secreted into the growth medium at levels of approximately
0.9 mg/ml by the L. lactis strains harboring pT1TT-IL2 and
pT1TT-IL6, respectively (Fig. 2B). Immunoblotting with anti-
IL-2 and anti-IL-6 antisera revealed that small quantities of
IL-2 and IL-6 were present in total cell extracts prepared from
the strains carrying plasmids pT1TT-IL2 and pT1TT-IL-6, re-
spectively (not shown). The IL-2 and IL-6 detected in these
total cell extracts were probably in their unprocessed forms
(signal sequence plus cytokine) since the proteins detected
were consistently found to be larger than purified IL-2 and
IL-6, respectively. The mature processed forms of these cyto-
kines were not detected in whole bacterial cell extracts or in
enzymatically degraded cell wall fractions of protoplasted bac-
teria, indicating that cytokines secreted by recombinant strains
of L. lactis were not being trapped in the cell wall.
Immunization of mice with live recombinant strains of
L. lactis secreting IL-2 or IL-6 potentiated antibody responses
to the coexpressed antigen TTFC. Groups of six C57BL/6 mice
were immunized intranasally with three doses of 109 CFU of
the various strains of recombinant lactococci on days 0, 14, and
28. The TTFC-specific serum antibody titers reached mean
endpoint titers of 104 to 105 in all mice which had been immu-
nized with lactococcal strains expressing TTFC compared to
FIG. 1. Schematic representation of pTREX1 (46) and the expression plasmids constructed for use in L. lactis. The location of unique restriction endonuclease sites,
promoter (p1), Shine-Dalgarno motif (SD), translation initiation start codon (ATG), and transcription terminator (E) present in the expression cassette of pTREX1
are indicated. The nucleotides encoding TTFC are numbered as previously described (12). In plasmids pT1TT-IL2, pT1TT-IL6, pT1-IL2, and pT1-IL6, the cDNA
fragments encoding mature forms of murine IL-2 and IL-6 (nucleotide numbering as in references 6 and 17) were fused to the secretion leader of L. lactis usp45
(nucleotide numbering as in reference 42).
FIG. 2. (A) Immunoblotting of whole-cell extracts from approximately 5 3
108 CFU of L. lactis MG1363 transformed with plasmid pTREX1, pT1TT,
pT1TT-IL2, or pT1TT-IL6 (as indicated) with rabbit polyclonal antiserum to
TTFC. (B) Amount of biologically active IL-2 or IL-6 detected in the culture
supernatant of the L. lactis strains based on the mean values of four separate
titrations as described previously for IL-2 and IL-6 (13, 44).
TABLE 1. Characteristics of recombinant strains of L. lactis
Strain description Plasmid
Nonexpressor control strain harboring expression
plasmid ..................................................................................pTREX1
Expresses and accumulates TTFC intracellularly................pT1TT
Secretes murine IL-2 and accumulates TTFC
intracellularly........................................................................pT1TT-IL2
Secretes murine IL-6 and accumulates TTFC
intracellularly........................................................................pT1TT-IL6
Secretes murine IL-2 ...............................................................pT1-IL2
Secretes murine IL-6 ...............................................................pT1-IL6
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mean endpoint titers of approximately 50 for naive mice and
mice inoculated with a nonexpressor control strain carrying
only the expression vector pTREX1. Strikingly, the anti-TTFC
antibody titers increased more rapidly and were substantially
(10- to 15-fold by day 35) higher in the groups of mice immu-
nized with the lactococcal strains coexpressing IL-2 (P 5
0.001) or IL-6 (P 5 0.001) than in the group immunized with
the strain expressing only TTFC (Fig. 3). On day 80 following
immunization, the mean TTFC antibody titers were still sig-
nificantly higher in the groups of mice immunized with the
recombinant L. lactis expressing IL-2 (P 5 0.040) or IL-6 (P 5
0.001) than in the group immunized with L. lactis expressing
only TTFC.
Both IgG1 and IgG2a subclasses of anti-TTFC antibody
were found in the sera of mice immunized with TTFC-express-
ing lactococci. The relative proportions of these antibody sub-
class-specific responses were not significantly different in mice
inoculated with the cytokine-secreting lactococci. As in previ-
ous studies (32), the serum antibody responses directed against
antigens of L. lactis were low (maximum endpoint titers be-
tween 50 and 500) in comparison with the anti-TTFC re-
sponses (Fig. 4). Interestingly, antibody responses directed
against antigenic components of L. lactis were not detectably
raised by coexpression of the cytokines. The substantial poten-
tiation of the anti-TTFC response in mice inoculated with the
IL-2- and IL-6-secreting lactococci appeared to be restricted to
the expressed heterologous protein.
Influence of cytokine coexpression by recombinant L. lactis
on IgA responses. To determine whether immunization with
recombinant lactococci coexpressing IL-6 or IL-2 would spe-
cifically enhance IgA responses, we assayed for TTFC-specific
IgA in the pooled serum from groups of animals immunized
intranasally with the different strains of L. lactis (Table 1).
Mice immunized with lactococci coexpressing IL-6 had serum
IgA antibodies to TTFC substantially higher than those of the
naive nonimmunized group of animals (Fig. 5). To determine
whether the cytokines secreted by recombinant L. lactis would
also influence the production of IgA in mucosal tissues, the
feces collected from groups of mice immunized intranasally
FIG. 3. Mean serum anti-TTFC IgG levels of groups of six mice intranasally
inoculated on days 0, 14, and 28 with 109 recombinant L. lactis as follows: n,
expressing TTFC (pT1TT); o, expressing TTFC and cosecreting IL-2 (pT1TT-
IL2); 1, expressing TTFC and cosecreting IL-6 (pT1TT-IL6); _^, control non-
expressor strain (pTREX1). Sera from a naive, nonvaccinated control group (h)
were also assayed. The endpoint titer was calculated as the dilution of serum
producing the same optical density as a 1/50 dilution of a pooled preimmune
serum included in six replicate wells on each plate. p, the endpoint titer was
significantly higher than those of the group inoculated with the pT1TT strain
(P . 0.05).
FIG. 4. Antilactococcal serum immunoglobulin responses of groups of six
mice intranasally inoculated on days 0, 14, and 28 () with 109 recombinant L.
lactis as follows: F, expressing TTFC (pT1TT); , expressing TTFC and cose-
creting IL-2 (pT1TT-IL2); , expressing TTFC and cosecreting IL-6 (pT1TT-
IL6); n, control nonexpressor strain (pTREX1). Sera from a naive, nonvacci-
nated group (M) were also assayed. The endpoint titer was calculated as the
dilution of serum producing the same optical density as a 1/50 dilution of a
pooled preimmune serum included in six replicate wells on each plate.
FIG. 5. Anti-TTFC IgA levels in pooled sera from groups of six mice intra-
nasally inoculated on days 0, 14, and 28 with 109 recombinant L. lactis as follows:
n, expressing TTFC (pT1TT); o, expressing TTFC and cosecreting IL-2
(pT1TT-IL2); 1, expressing TTFC and cosecreting IL-6 (pT1TT-IL6); _^, con-
trol nonexpressor strain (pTREX1). Sera from a naive, nonvaccinated control
group (h) were also assayed. The endpoint titer in the ELISA was calculated as
the dilution of serum producing the same optical density as a 1/50 dilution of a
pooled preimmune serum included in six replicate wells on each plate.
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with different doses of recombinant L. lactis and a naive con-
trol group of mice were assayed for total IgA content by using
a commercially available radial immunodiffusion kit. At 35
days postimmunization (7 days after the final boost), the con-
centrations of IgA measured in the soluble extracts prepared
from fecal material were similar for both immunized and naive
groups of mice (results not shown). These results suggest that
intranasal immunization with IL-6- or IL-2-secreting L. lactis
had no measurable effect on total IgA production in the gas-
trointestinal tract.
Influence of lactococcal cell viability on immune responses
elicited by recombinant L. lactis. Groups of six mice were
immunized with live or mitomycin C-killed strains of L. lactis
to determine whether effective cytokine delivery, as deter-
mined by the adjuvant effect of the anti-TTFC antibody re-
sponse, was dependent on the production of active cytokine in
vivo (rather than being due to the possible release of pre-
formed, bacterially associated cytokine in the animal). All mice
immunized with the TTFC-expressing strains of L. lactis elic-
ited serum antibody responses to TTFC with peak endpoint
titers of 2 3 103 to 3 3 104, compared to mean endpoint titers
of approximately 50 for naive mice and control mice inoculated
with a nonexpressor control strain (Fig. 6). The mean antibody
titers elicited by live and killed L. lactis expressing only TTFC
were not significantly different on any of the days on which
serum was sampled (Fig. 6), showing (as have our previous
results [25, 32]) that antigen expression in vivo is not required
to elicit an immune response to TTFC expressed intracellularly
in lactococci. However, when the cytokine-secreting strains of
L. lactis were treated with mitomycin C, the titers of anti-TTFC
antibodies were not significantly different from those elicited
by bacteria expressing TTFC alone, indicating that cytokine-
secreting strains of lactococci need to be viable in vivo for
effective cytokine delivery to occur (Fig. 6).
DISCUSSION
The results presented here indicate that it is possible to
construct physiologically active antigen- and cytokine-express-
ing recombinant strains of L. lactis and that these strains ap-
pear to constitute a simple and effective means of delivering
murine IL-2 and murine IL-6 across mucosal surfaces to the
immune system.
This study was made possible by constructing an artificial
bicistronic operon within the constitutive expression plasmid
pTREX1 to yield strains of L. lactis which secrete IL-2 or IL-6
and also coexpress TTFC and accumulate this protein intra-
cellularly. These bacteria secreted biologically active IL-2 or
IL-6 and elicited significantly (10- to 15-fold) higher TTFC
antibody titers than did the strains expressing only TTFC (Fig.
3). As the amounts of TTFC produced by the different strains
were similar, and since we have found (unpublished results)
that the TTFC antibody titers elicited by recombinant strains
of L. lactis expressing 10-fold-higher levels of TTFC antigen
are not substantially different, the enhanced anti-TTFC im-
mune responses must be directly attributable to the coexpres-
sion of IL-2 or IL-6.
The influence of cytokine coexpression by recombinant lac-
tococci on IgA responses was investigated by measuring the
serum levels of anti-TTFC IgA and total IgA recovered in the
feces of mice immunized with the various strains of L. lactis.
Elevated serum anti-TTFC IgA responses were seen only in
mice immunized with recombinant lactococci secreting IL-6.
These TTFC-specific IgA serum responses were elevated even
after the primary dose but increased over time for at least 80
days postimmunization (Fig. 5). Although the differences be-
tween the IgA levels measured in the IL-6 group of animals
and those of the naive and control groups were small (up to
twofold), these differences are significant since we have never
previously been able to measure serum IgA responses to TTFC
following immunization with recombinant TTFC-expressing
lactococci which differed from those of the naive or nonexpres-
FIG. 6. Influence of lactococcal cell viability on the immune responses elic-
ited by IL-2-secreting (a) and IL-6-secreting (b) L. lactis. Shown are mean
anti-TTFC serum antibody responses of groups of six mice following intranasal
administration of 109 live (closed symbols) or mitomycin C-killed (open symbols)
recombinant L. lactis strains on days 0, 14, and 28 () as follows: F, expressing
TTFC (pT1TT); , expressing TTFC and cosecreting IL-2 (pT1TT-IL2); ,
expressing TTFC and cosecreting IL-6 (pT1TT-IL6); n, control nonexpressor
strain (pTREX1); }, secreting IL-2 (pT1-IL2); , secreting IL-6 (pT1-IL6). Sera
from a naive, nonvaccinated group (M) were also assayed. The endpoint titer was
calculated as the dilution of serum producing the same optical density as a 1/50
dilution of a pooled preimmune serum included in six replicate wells on each
plate.
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sor control groups. The amounts of total IgA measured in fecal
material were not increased in the groups immunized with the
cytokine-secreting strains of L. lactis. However, further exper-
iments aimed at measuring IgA levels in mucosal secretions at
various times after immunization with cytokine-secreting L.
lactis by different routes will be needed before any firm con-
clusions can be drawn as to their possible effects on IgA pro-
duction in mucosal tissues.
By comparison with the marked enhancement of the serum
anti-TTFC IgG antibody titers seen here, it was striking that
the antibody responses to lactococci were not elevated in mice
inoculated with the strains coexpressing IL-2 or IL-6 (maxi-
mum ELISA titers of 400 in all groups of mice [Fig. 4]). We
have previously observed that lactococci appear to have a low
innate antigenicity. This property may be advantageous if the
use of repeated administration of recombinant lactococci is
required.
The mode of action of the cytokine-secreting strains on the
immune system requires further investigation. Lactococci are
sufficiently small (about 1 mm in diameter) to be taken up by
microfold cells present in the follicular epithelium overlaying
the mucosa-associated lymphoid tissue. We have shown in this
report and previously that these bacteria resemble inert micro-
particles to the extent that effective presentation of TTFC by
lactococci to the immune system does not require bacterial
viability (25, 32). By contrast, the adjuvant effect on the im-
mune responses to TTFC observed with the live cytokine-
secreting strains was lost when the bacteria were treated with
lethal doses of mitomycin C prior to immunization (Fig. 6).
This result constitutes the most direct evidence that lactococci
can deliver cytokines in vivo and that the adjuvant effect of
cytokine coexpression and secretion by lactococci is due to a
level of continued physiological activity by the lactococci in
vivo. An alternative explanation would be that the adjuvant
effects observed here were due to the release of preformed,
bacterially associated cytokines by live but not by mitomycin-
killed L. lactis. We cannot completely preclude this possibility
but consider it unlikely, in view of the fact that we could not
detect processed cytokines in the digested cell wall fractions of
live protoplasted cytokine-expressing bacteria.
The finding that L. lactis can be used to deliver biologically
active cytokines to the immune system in vivo is surprising
because L. lactis is not a commensal bacterium and is not
known to replicate in vivo. The fate of intranasally inoculated
L. lactis is also not known, although it is likely that a proportion
of any inoculum given intranasally may be inhaled and then
enter the lungs or be swallowed and enter the gastrointestinal
tract. Physiological studies of the murine nasal-associated mu-
cosal immune system indicate that antigens and pathogens
encountered at the nasal epithelium will be sampled by micro-
fold cells and transported to the underlying lymphoid tissue,
where they can induce an immune response (2, 19). Here the
local production of IL-2 or IL-6 by L. lactis may stimulate early
proliferation of mucosal T cells or augment B-cell growth
and/or differentiation and immunoglobulin production (5, 28,
39, 41, 43). The results presented here suggest that it may be
possible to tailor the type of immune response elicited to
antigens delivered by lactococci through the expression of ap-
propriate cytokines and in such way lead to an appropriate
vaccination strategy against a particular pathogen. The striking
fact that a pulse of cytokines can be delivered by recombinant
lactococci in this way also raises interesting and testable ques-
tions concerning the possible therapeutic uses of such recom-
binant bacteria.
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